Home › Compare › RUBY vs O

RUBY vs O: Dividend Comparison 2026

RUBY yields 3508.77% · O yields 5.28%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 RUBY wins by $2034141393542.05M in total portfolio value
10 years
RUBY
RUBY
● Live price
3508.77%
Share price
$0.06
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$2034141393542.08M
Annual income
$1,926,153,862,282,748,700.00
Full RUBY calculator →
O
Realty Income Corporation
● Live price
5.28%
Share price
$61.15
Annual div
$3.23
5Y div CAGR
15.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$34.2K
Annual income
$5,102.74
Full O calculator →

Portfolio growth — RUBY vs O

📍 RUBY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodRUBYO
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, RUBY + O cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
RUBY pays
O pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

RUBY
Annual income on $10K today (after 15% tax)
$298,245.61/yr
After 10yr DRIP, annual income (after tax)
$1,637,230,782,940,336,400.00/yr
O
Annual income on $10K today (after 15% tax)
$449.12/yr
After 10yr DRIP, annual income (after tax)
$4,337.33/yr
At 15% tax rate, RUBY beats the other by $1,637,230,782,940,332,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of RUBY + O for your $10,000?

RUBY: 50%O: 50%
100% O50/50100% RUBY
Portfolio after 10yr
$1017070696771.06M
Annual income
$963,076,931,141,376,900.00/yr
Blended yield
94.69%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on O right now

RUBY
Analyst Ratings
5
Buy
3
Hold
1
Sell
Consensus: Buy
Altman Z
-81.9
Piotroski
2/9
O
Analyst Ratings
13
Buy
18
Hold
3
Sell
Consensus: Hold
Price Target
$64.00
+4.7% upside vs current
Range: $60.00 — $69.00
Altman Z
1.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

RUBY buys
0
O buys
0
No recent congressional trades found for RUBY or O in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricRUBYO
Forward yield3508.77% ✓5.28%
Annual dividend / share$2.00$3.23 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.1% ✓
Portfolio after 10y$2034141393542.08M ✓$34.2K
Annual income after 10y$1,926,153,862,282,748,700.00 ✓$5,102.74
Total dividends collected$2026733119198.63M ✓$20.7K
Payment frequencyquarterlymonthly
SectorStockREIT
Analyst consensusBuyHold

Year-by-year: RUBY vs O ($10,000, DRIP)

YearRUBY PortfolioRUBY Income/yrO PortfolioO Income/yrGap
1← crossover$361,577$350,877.19$10,818$608.16+$350.8K → RUBY
2$12,243,821$11,856,933.69$11,787$741.68+$12.23M → RUBY
3$388,336,948$375,236,059.53$12,946$911.00+$388.32M → RUBY
4$11,538,279,357$11,122,758,822.00$14,345$1,127.94+$11538.27M → RUBY
5$321,205,540,543$308,859,581,631.20$16,056$1,409.05+$321205.52M → RUBY
6$8,379,307,864,544$8,035,617,936,162.96$18,171$1,777.83+$8379307.85M → RUBY
7$204,877,671,222,196$195,911,811,807,134.25$20,820$2,268.21+$204877671.20M → RUBY
8$4,695,974,086,156,479$4,476,754,977,948,728.50$24,188$2,929.90+$4695974086.13M → RUBY
9$100,922,926,410,592,910$95,898,234,138,405,470.00$28,533$3,837.11+$100922926410.56M → RUBY
10$2,034,141,393,542,082,800$1,926,153,862,282,748,700.00$34,235$5,102.74+$2034141393542.05M → RUBY

RUBY vs O: Complete Analysis 2026

RUBY — Stock

Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of solid tumors cancer; and RTX-aAPC to treat cancers. It is also developing RTX-321 for the treatment of HPV-positive tumors; and RTX-T1D for treating type 1 diabetes. The company was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.

Full RUBY Calculator →

O — REIT

Realty Income, The Monthly Dividend Company, is an S&P 500 company dedicated to providing stockholders with dependable monthly income. The company is structured as a REIT, and its monthly dividends are supported by the cash flow from over 6,500 real estate properties owned under long-term lease agreements with our commercial clients. To date, the company has declared 608 consecutive common stock monthly dividends throughout its 52-year operating history and increased the dividend 109 times since Realty Income's public listing in 1994 (NYSE: O). The company is a member of the S&P 500 Dividend Aristocrats index. Additional information about the company can be obtained from the corporate website at www.realtyincome.com.

Full O Calculator →
📬

Get this RUBY vs O comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

RUBY vs SCHDRUBY vs JEPIRUBY vs KORUBY vs MAINRUBY vs STAGRUBY vs ADCRUBY vs NNNRUBY vs VICI

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.